VIM and breast carcinoma: Treatment with SMRwt of MDA-MB-231 and MCF-7 breast cancer cells resulted in lowered exosome protein expression of Mortalin to 31.02% and 22.88% and Vimentin to 41.14% and 53.31% (Fig. 5B).